A new UK study found that swearing appeared to lessen the effects of pain, perhaps because it invokes a similar response as that which occurs in fight or flight when it breaks the link between fear of pain and the perception of pain, concluded the researchers. The study was the work of psychologists Richard Stephens, John Atkins and Andrew Kingston at Keele University in Staffordshire, and was recently published in the journal NeuroReport. Although swearing is a common response to pain, whether it actually alters our experience of it is somewhat of a mystery. According to a Reuters news agency report, Stephens said: "Swearing has been around for centuries and is an almost universal human linguistic phenomenon.
When we are feeling blue we are told to count our blessings, but according to a study recently published in Psychological Science, counting our money might be a more useful activity. Psychologists Xinyue Zhou, Sun Yat-Sen University, Kathleen D. Vohs, University of Minnesota, and Roy F. Baumeister, Florida State University, investigated the psychological, physical and social impact of money. To examine this, the researchers asked one group of participants to count out eighty $100 bills and another group to count eighty worthless pieces of paper. They then played a computerized ball-tossing game called Cyperball. The participants were led to believe that they were playing with three other gamers when the other players in fact were computer generated.
A team of Massachusetts General Hospital (MGH) physicians has developed a new general anesthetic that may be safer for critically ill patients. In the August issue of Anesthesiology, they describe preclinical studies of the drug called MOC-etomidate - a chemically altered version of an exiting anesthetic - which does not cause the sudden drop in blood pressure seen with most anesthetics or prolonged suppression of adrenal gland activity, a problem with the original version of the drug. "We have shown that making a version of etomidate that is broken down very quickly in the body reduces the duration of adrenal suppression while retaining etomidate's benefit of keeping blood pressure much more stable than other anesthetics do, " says Douglas Raines, MD, of the MGH Department of Anesthesia, Critical Care and Pain Medicine, who led the study.
QRxPharma Limited (Pink Sheets: QRXPY; ASX: QRX) announced the initiation of a Phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo(TM) IV (intravenous morphine and oxycodone ) versus IV morphine alone for the treatment of moderate to severe post-operative pain in patients following hip replacement surgery. Data from this study will serve as a significant predictor of MoxDuo(TM) IV's clinical benefits and provide guidance for the design of further clinical trials leading to submission of an NDA to the US Food and Drug Administration (FDA) within the next three years. "QRxPharma's goal is to bring to market complementary analgesic options for pain specialists, delivering greater patient tolerability and efficacy than current standards of care.
Allergan Receives FDA Approval For ACUVAIL trade; Ophthalmic Solution For The Treatment Of Pain And Inflammation Following Cataract Surgery
Allergan, Inc. (NYSE: AGN) announced that the United States Food and Drug Administration (FDA) has approved ACUVAIL™ (ketorolac tromethamine ophthalmic solution) 0.45%, an advanced, preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery. Cataracts are a leading cause of blindness among older adults and cataract surgery is the most frequently performed surgical procedure in the United States, with more than 3 million procedures performed each year.1 ACUVAIL™ is formulated at pH 6.8, enabling deionized drug delivery on the corneal surface.
Menstrual cramps, also known as dysmenorrhea or period pains, are painful sensations felt in the lower abdomen that can occur both before and during a woman's menstrual period. The pain ranges from dull and annoying to severe and extreme. Menstrual cramps tend to begin after an egg is released from the ovaries and travels down the fallopian tube (ovulation). There are two primary types of these difficult or painful periods - primary and secondary dysmenorrhea: Primary dysmenorrhea is the most common type and is characterized by pain in the lower abdomen and lower back pain beginning 1-2 days before the period and lasting from 2 to 4 days.